Evidence map›Paper›PMID 40904938›Full record

ReviewJournal of hematology2025

Mast Cell Leukemia: Comprehensive Review of Literature With Current Insights and Updates on Management.

Muralidhar Idamakanti, Ala Ebaid, Rani Indrani Bijjam, Alexei Bakhirev

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Muralidhar IdamakantiAdult Internal Medicine Services (AIMS), Presbyterian Healthcare Services (PHS), Albuquerque, NM 87106, USA.ORCID https://orcid.org/0009-0004-3599-3003
Ala EbaidDivision of Hematology/Oncology, The University of New Mexico Comprehensive Cancer Center (UNMCC), Albuquerque, NM 87102, USA.
Rani Indrani BijjamAdult Internal Medicine Services (AIMS), Presbyterian Healthcare Services (PHS), Albuquerque, NM 87106, USA.
Alexei BakhirevPathology Associates of Albuquerque (PAA), Albuquerque, NM 87106, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mast cell leukemia (MCL) is an exceedingly rare and aggressive variant of systemic mastocytosis (SM). MCL is classified as primary, occurring

Indexed as

Advanced systemic mastocytosisAvapritinibHematopoietic stem cell transplantationImmunomodulatory therapyKIT D816V mutationMast cell activation syndromeMast cell leukemiaMidostaurinOverall survivalSystemic mastocytosisTyrosine kinase inhibitors

Identifiers

PMID40904938
PMCPMC12404107

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.